SOURCE-LINKED INTELLIGENCE

Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation

CORDIS · observation · Publication date unknown

Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation Celeris Therapeutics is a deep learning company that uses innovative, in-silico methods such as geometric deep learning and graph neural networks to degrade currently undruggable targets (pathogenic proteins). The platform shall make a broad impact by addressing currently incureable diseases such as Alzheimer's, Parkinson's, and different types of cancer like breast and prostate cancer. Celeris Therapeutics' technical solution is the web application (orchestration platform) Celeris One. It consists of three modules: Hades (target ID), Xanthos (predicting biomolecular interactions and ligand design), Hephaistos (automated synthesize and validate). The addressed market is in the early-stage drug discovery and users are pharmaceutical and biotech companies with a focus on Targeted Protein Degrad

Read original source ↗ Open in workspace

recordType

award

status

CLOSED

region

EU

value

2500000

unit

EUR